{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T10:02:22Z","timestamp":1790762542436,"version":"4.1.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T00:00:00Z","timestamp":1789689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T00:00:00Z","timestamp":1789689600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ophthalmologie"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1007\/s00347-026-02543-4","type":"journal-article","created":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T13:41:52Z","timestamp":1789738912000},"page":"832-842","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Infantile H\u00e4mangiome: diagnostische und therapeutische Vorgehensweise","Infantile hemangiomas: diagnosis and modern therapeutic approaches"],"prefix":"10.1007","volume":"123","author":[{"given":"Friedrich G.","family":"Kapp","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hagen","family":"Ott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,18]]},"reference":[{"key":"2543_CR1","doi-asserted-by":"publisher","unstructured":"Goldenberg DC, Vikkula M, Penington A et\u00a0al. (2025) Updated Classification of Vascular Anomalies: A\u00a0living document from the International Society for the Study of Vascular Anomalies Classification Group. Journal of Vascular Anomalies 6:e113. https:\/\/doi.org\/10.1097\/JOVA.0000000000000113","DOI":"10.1097\/JOVA.0000000000000113"},{"key":"2543_CR2","doi-asserted-by":"publisher","unstructured":"Luu M, Frieden IJ (2013) Haemangioma: clinical course, complications and management. Br J Dermatol 169:20\u201330. https:\/\/doi.org\/10.1111\/bjd.12436","DOI":"10.1111\/bjd.12436"},{"key":"2543_CR3","doi-asserted-by":"publisher","unstructured":"Kleinman ME, Greives MR, Churgin SS et\u00a0al. (2007) Hypoxia-Induced Mediators of Stem\/Progenitor Cell Trafficking Are Increased in Children With Hemangioma. ATVB 27:2664\u20132670. https:\/\/doi.org\/10.1161\/ATVBAHA.107.150284","DOI":"10.1161\/ATVBAHA.107.150284"},{"key":"2543_CR4","doi-asserted-by":"publisher","unstructured":"Seebauer CT, Graus MS, Lan Huang et\u00a0al. (2022) Non\u2013beta blocker enantiomers of propranolol and atenolol inhibit vasculogenesis in infantile hemangioma. Journal of Clinical Investigation 132:e151109. https:\/\/doi.org\/10.1172\/JCI151109","DOI":"10.1172\/JCI151109"},{"key":"2543_CR5","doi-asserted-by":"publisher","unstructured":"O\u2019Brien KF, Shah SD, Pope E et\u00a0al. (2019) Late growth of infantile hemangiomas in children \u3009\u202f3\u00a0years of age: A\u00a0retrospective study. Journal of the American Academy of Dermatology 80:493\u2013499. https:\/\/doi.org\/10.1016\/j.jaad.2018.07.061","DOI":"10.1016\/j.jaad.2018.07.061"},{"key":"2543_CR6","doi-asserted-by":"publisher","unstructured":"North PE, Waner M, James CA et\u00a0al. (2001) Congenital Nonprogressive Hemangioma: A\u00a0Distinct Clinicopathologic Entity Unlike Infantile Hemangioma. Arch Dermatol. https:\/\/doi.org\/10.1001\/archderm.137.12.1607","DOI":"10.1001\/archderm.137.12.1607"},{"key":"2543_CR7","doi-asserted-by":"publisher","unstructured":"Ayturk UM, Couto JA, Hann S et\u00a0al. (2016) Somatic Activating Mutations in GNAQ and GNA11 Are Associated with Congenital Hemangioma. The American Journal of Human Genetics 98:789\u2013795. https:\/\/doi.org\/10.1016\/j.ajhg.2016.03.009","DOI":"10.1016\/j.ajhg.2016.03.009"},{"key":"2543_CR8","doi-asserted-by":"publisher","unstructured":"Borst AJ, Eng W, Griffin M et\u00a0al. (2024) Treatment practices and response in kaposiform hemangioendothelioma: A\u00a0multicenter cohort study. Pediatric Blood & Cancer 71:e30779. https:\/\/doi.org\/10.1002\/pbc.30779","DOI":"10.1002\/pbc.30779"},{"key":"2543_CR9","doi-asserted-by":"publisher","unstructured":"Seo SK, Suh JC, Na GY et\u00a0al. (1999) Kasabach-Merritt syndrome: identification of platelet trapping in a\u00a0tufted angioma by immunohistochemistry technique using monoclonal antibody to CD61. Pediatr Dermatol 16:392\u2013394. https:\/\/doi.org\/10.1046\/j.1525-1470.1999.00103.x","DOI":"10.1046\/j.1525-1470.1999.00103.x"},{"key":"2543_CR10","doi-asserted-by":"publisher","unstructured":"Corbeddu M, Meucci D, Diociaiuti A et\u00a0al. (2021) Management of Upper Airway Infantile Hemangiomas: Experience of One Italian Multidisciplinary Center. Front Pediatr 9:717232. https:\/\/doi.org\/10.3389\/fped.2021.717232","DOI":"10.3389\/fped.2021.717232"},{"key":"2543_CR11","doi-asserted-by":"publisher","unstructured":"Diociaiuti A, Baselga E, Boon LM et\u00a0al. (2022) The VASCERN-VASCA working group diagnostic and management pathways for severe and\/or rare infantile hemangiomas. European Journal of Medical Genetics 65:104517. https:\/\/doi.org\/10.1016\/j.ejmg.2022.104517","DOI":"10.1016\/j.ejmg.2022.104517"},{"key":"2543_CR12","doi-asserted-by":"publisher","unstructured":"Frieden IJ (1996) PHACE Syndrome: The Association of Posterior Fossa Brain Malformations, Hemangiomas, Arterial Anomalies, Coarctation of the Aorta and Cardiac Defects, and Eye Abnormalities. Arch Dermatol 132:307. https:\/\/doi.org\/10.1001\/archderm.1996.03890270083012","DOI":"10.1001\/archderm.1996.03890270083012"},{"key":"2543_CR13","doi-asserted-by":"publisher","unstructured":"Braun M, Frieden IJ, Siegel DH et\u00a0al. (2024) Multicenter Study of Long-Term Outcomes and Quality of Life in PHACE Syndrome after Age 10. The Journal of Pediatrics 267:113907. https:\/\/doi.org\/10.1016\/j.jpeds.2024.113907","DOI":"10.1016\/j.jpeds.2024.113907"},{"key":"2543_CR14","doi-asserted-by":"publisher","unstructured":"Martin B, Bui JK, Corpin A et\u00a0al. (2025) LUMBAR Syndrome State-Of-The-Art Review: Insights Into a\u00a0Rare and Complex Condition. Pediatric Dermatology 42:1117\u20131125. https:\/\/doi.org\/10.1111\/pde.70024","DOI":"10.1111\/pde.70024"},{"key":"2543_CR15","doi-asserted-by":"publisher","unstructured":"Kulungowski AM, Alomari AI, Chawla A et\u00a0al. (2012) Lessons from a\u00a0liver hemangioma registry: subtype classification. Journal of Pediatric Surgery 47:165\u2013170. https:\/\/doi.org\/10.1016\/j.jpedsurg.2011.10.037","DOI":"10.1016\/j.jpedsurg.2011.10.037"},{"key":"2543_CR16","doi-asserted-by":"publisher","unstructured":"Huang SA, Tu HM, Harney JW et\u00a0al. (2000) Severe Hypothyroidism Caused by Type\u00a03 Iodothyronine Deiodinase in Infantile Hemangiomas. N Engl J Med 343:185\u2013189. https:\/\/doi.org\/10.1056\/NEJM200007203430305","DOI":"10.1056\/NEJM200007203430305"},{"key":"2543_CR17","doi-asserted-by":"publisher","unstructured":"Bessis D, Bigorre M, Labr\u00e8ze C (2015) Reticular infantile hemangiomas with minimal or arrested growth associated with lipoatrophy. Journal of the American Academy of Dermatology 72:828\u2013833. https:\/\/doi.org\/10.1016\/j.jaad.2015.01.028","DOI":"10.1016\/j.jaad.2015.01.028"},{"key":"2543_CR18","doi-asserted-by":"publisher","unstructured":"Krowchuk DP, Frieden IJ, Mancini AJ et\u00a0al. (2019) Clinical Practice Guideline for the Management of Infantile Hemangiomas. Pediatrics 143:e20183475. https:\/\/doi.org\/10.1542\/peds.2018-3475","DOI":"10.1542\/peds.2018-3475"},{"key":"2543_CR19","doi-asserted-by":"publisher","unstructured":"Colmenero-Sendra M, del Boz-Gonz\u00e1lez J, Grau-P\u00e9rez M et\u00a0al. (2025) Interobserver and Intraobserver Agreement on the Treatment of Infantile Hemangiomas. JAMA Dermatol 161:203. https:\/\/doi.org\/10.1001\/jamadermatol.2024.5125","DOI":"10.1001\/jamadermatol.2024.5125"},{"key":"2543_CR20","doi-asserted-by":"publisher","unstructured":"Barlow CF, Priebe CJ, Mulliken JB et\u00a0al. (1998) Spastic diplegia as a\u00a0complication of interferon Alfa-2a treatment of hemangiomas of infancy. The Journal of Pediatrics 132:527\u2013530. https:\/\/doi.org\/10.1016\/S0022-3476(98)70034-4","DOI":"10.1016\/S0022-3476(98)70034-4"},{"key":"2543_CR21","doi-asserted-by":"publisher","unstructured":"L\u00e9aut\u00e9-Labr\u00e8ze C, Hoeger P, Mazereeuw-Hautier J et\u00a0al. (2015) A Randomized, Controlled Trial of Oral Propranolol in Infantile Hemangioma. N Engl J Med 372:735\u2013746. https:\/\/doi.org\/10.1056\/NEJMoa1404710","DOI":"10.1056\/NEJMoa1404710"},{"key":"2543_CR22","doi-asserted-by":"publisher","unstructured":"L\u00e9aut\u00e9-Labr\u00e8ze C, de la Roque ED, Hubiche T et\u00a0al. (2008) Propranolol for Severe Hemangiomas of Infancy. N Engl J Med 358:2649\u20132651. https:\/\/doi.org\/10.1056\/NEJMc0708819","DOI":"10.1056\/NEJMc0708819"},{"key":"2543_CR23","doi-asserted-by":"publisher","unstructured":"Zhang K, Qiu T, Zhou J et\u00a0al. (2025) Timing of treatment with oral propranolol for infantile hemangioma. BMC Pediatr 25:684. https:\/\/doi.org\/10.1186\/s12887-025-06033-5","DOI":"10.1186\/s12887-025-06033-5"},{"key":"2543_CR24","doi-asserted-by":"publisher","unstructured":"Hu J, Pan L, Kong H, Lou J (2026) A Systematic Review and Meta-Analysis of the Efficacy and Safety of Propranolol Versus Other Drugs in the Treatment of Infantile Hemangioma. J\u00a0of Cosmetic Dermatology 25:e70750. https:\/\/doi.org\/10.1111\/jocd.70750","DOI":"10.1111\/jocd.70750"},{"key":"2543_CR25","doi-asserted-by":"publisher","unstructured":"Fern\u00e1ndez Faith E, Shah S, Witman PM et\u00a0al. (2021) Clinical Features, Prognostic Factors, and Treatment Interventions for Ulceration in Patients With Infantile Hemangioma. JAMA Dermatol 157:566. https:\/\/doi.org\/10.1001\/jamadermatol.2021.0469","DOI":"10.1001\/jamadermatol.2021.0469"},{"key":"2543_CR26","doi-asserted-by":"publisher","unstructured":"Ashraf R, Mahajan R, Malik MA et\u00a0al. (2023) Comparing the Effectiveness of Propranolol versus Atenolol in Inducing Clinical Clearance in the Treatment of Infantile Haemangioma: A\u00a0Randomised Controlled Trial. Indian Journal of Dermatology 68:148\u2013155. https:\/\/doi.org\/10.4103\/ijd.ijd_867_22","DOI":"10.4103\/ijd.ijd_867_22"},{"key":"2543_CR27","doi-asserted-by":"publisher","unstructured":"Lopes FCPS, Levy ML, Ruth JS et\u00a0al. (2025) Sirolimus in the Management of Complex Infantile Hemangiomas: A\u00a0State-of-the-Art Review. Pediatric Dermatology 42:1126\u20131132. https:\/\/doi.org\/10.1111\/pde.70071","DOI":"10.1111\/pde.70071"},{"key":"2543_CR28","doi-asserted-by":"publisher","unstructured":"Holm A, Graus MS, Wylie-Sears J et\u00a0al. (2025) An endothelial SOX18\u2013mevalonate pathway axis enables repurposing of statins for infantile hemangioma. Journal of Clinical Investigation 135:e179782. https:\/\/doi.org\/10.1172\/JCI179782","DOI":"10.1172\/JCI179782"}],"container-title":["Die Ophthalmologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00347-026-02543-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00347-026-02543-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00347-026-02543-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T09:18:38Z","timestamp":1790759918000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00347-026-02543-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,18]]},"references-count":28,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["2543"],"URL":"https:\/\/doi.org\/10.1007\/s00347-026-02543-4","relation":{},"ISSN":["2731-720X","2731-7218"],"issn-type":[{"value":"2731-720X","type":"print"},{"value":"2731-7218","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,18]]},"assertion":[{"value":"18 September 2026","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Gem\u00e4\u00df den Richtlinien des Springer Medizin Verlags werden Autorinnen und Autoren sowie die Wissenschaftliche Leitung im Rahmen der Manuskripterstellung und Manuskriptfreigabe aufgefordert, eine vollst\u00e4ndige Erkl\u00e4rung zu ihren finanziellen und nichtfinanziellen Interessen abzugeben.","order":1,"name":"Ethics","label":"Interessenkonflikt","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"F.G.\u00a0Kapp\n                      : A.\u00a0Finanzielle Interessen: BMFTR: finanzielle Forschungsf\u00f6rderung im Rahmen eines EJPRD-Projektes, Tour der Hoffnung: finanzielle Forschungsf\u00f6rderung, Studienleiter bei klinischen Studien (Novartis).\u00a0\u2013 Beratergeb\u00fchren (Novartis, AOP Health und Pierre Fabre), Mitglied in Scientific Committees (Novartis).\u00a0\u2013 B.\u00a0Nichtfinanzielle Interessen: Angestellter Oberarzt f\u00fcr Kinderonkologie, Fokus auf Gef\u00e4\u00dfmalformationen und -tumoren | Mitglied in VASCERN und Mitbegr\u00fcnder des DRN Gef\u00e4\u00dfanomalien | Mitgliedschaften: ISSVA, GPOH, DGKJ, DiGGefa, EHA, Marburger Bund.\n                      H.\u00a0Ott\n                      : A.\u00a0Finanzielle Interessen: Hauner Verein M\u00fcnchen. | F\u00f6rderung eines Projekts zur Teledermatologie, keine finanziellen oder nichtfinanziellen Interessen in Zusammenhang mit o.\u202fg. Fortbildungstitel | Keine finanziellen Zuwendungen anderer Institutionen und insbesondere nicht von kommerziellen Unternehmen. | Vortragst\u00e4tigkeiten auf Fortbildungsveranstaltungen von Universit\u00e4ten, Fachgesellschaften und beim DermaUpdate 2021, 2023 und 2025.\u00a0\u2013 B.\u00a0Nichtfinanzielle Interessen: Facharzt f\u00fcr Kinder- und Jugendmedizin, Facharzt f\u00fcr Haut- und Geschlechtskrankheiten; Angestellt als leitender Arzt der Sektion f\u00fcr integrierte Kinderdermatologie im integrierten sozialp\u00e4diatrischen Zentrum am Dr. von Haunerschen Kinderspital in M\u00fcnchen (iSPZ Hauner MUC) und als Facharzt in der Klinik f\u00fcr Kinderchirurgie am Dr. von Haunerschen Kinderspital in M\u00fcnchen | 2.\u00a0Vorsitzender der Arbeitsgemeinschaft f\u00fcr P\u00e4diatrische Dermatologie in der Deutschen Dermatologischen Gesellschaft, Vorstandsmitglied (Board Member) in der European Society for Pediatric Dermatology, Mitglied im erweiterten Vorstand der Gesellschaft f\u00fcr P\u00e4diatrische Allergologie und Umweltmedizin, Mitglied im erweiterten Vorstand der Deutschen Gesellschaft f\u00fcr Allergologie und klinische Immunologie, Ehrenmitglied der \u00f6sterreichischen Arbeitsgemeinschaft f\u00fcr P\u00e4diatrische Dermatologie | Mitgliedschaften (Auswahl): Deutsche Gesellschaft f\u00fcr Kinder- und Jugendmedizin, Deutsche interdisziplin\u00e4re Gesellschaft f\u00fcr Gef\u00e4\u00dfanomalien, Royal Society of Medicine.","order":2,"name":"Ethics","label":"Autorinnen und Autoren","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"Die vollst\u00e4ndige Erkl\u00e4rung zum Interessenkonflikt der Wissenschaftlichen Leitung finden Sie am Kurs der zertifizierten Fortbildung auf\n                      \n                      .","order":3,"name":"Ethics","label":"Wissenschaftliche Leitung","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"erkl\u00e4rt, dass f\u00fcr die Publikation dieser CME-Fortbildung keine Sponsorengelder an den Verlag flie\u00dfen.","order":4,"name":"Ethics","label":"Der Verlag","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autoren keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien. F\u00fcr Bildmaterial oder anderweitige Angaben innerhalb des Manuskripts, \u00fcber die Patient\/-innen zu identifizieren sind, liegt von ihnen und\/oder ihren gesetzlichen Vertretern\/Vertreterinnen eine schriftliche Einwilligung vor.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}}]}}